Author/Authors :
Ishitsuka، نويسنده , , Kenji and Kunami، نويسنده , , Naoko and Katsuya، نويسنده , , Hiroo and Nogami، نويسنده , , Rumiko and Ishikawa، نويسنده , , Chie and Yotsumoto، نويسنده , , Fusanori and Tanji، نويسنده , , Hiroe and Mori، نويسنده , , Naoki and Takeshita، نويسنده , , Morishige and Miyamoto، نويسنده , , Shingo and Tamura، نويسنده , , Kazuo، نويسنده ,
Abstract :
Adult T-cell leukemia/lymphoma (ATLL) is a peripheral T-cell malignancy caused by human T-lymphotropic virus type I (HTLV-1). ABT-737, a small molecule inhibitor of Bcl-2, Bcl-XL, and Bcl-w, significantly induced apoptosis in HTLV-1 infected T-cell lines as well as in fresh ATLL cells, and synergistically enhanced the cytotoxicity and apoptosis induced by conventional cytotoxic drugs. Moreover, ABT-737 significantly inhibited the in vivo tumor growth of an ATLL mouse model. These results suggest that the use of an agent targeting anti-apoptotic bcl-2 family proteins, either alone or in combination with other conventional drugs, represents a novel promising approach for ATLL.
Keywords :
ATLL , Bcl-2 family proteins , apoptosis , Novel treatment , ABT-737
